Joseph Oliveto - 07 Jan 2026 Form 4 Insider Report for Milestone Pharmaceuticals Inc. (MIST)

Role: President and CEO, Director
Signature: /s/ Joseph Oliveto
Issuer symbol: MIST
Transactions as of: 07 Jan 2026
Net transactions value: -$97,875
Form type: 4
Filing time: 09 Jan 2026, 16:53:39 UTC
Previous filing: 28 Jan 2026
Next filing: 05 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Oliveto Joseph	President and CEO, Director	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL, QUEBEC, CANADA	/s/ Joseph Oliveto	09 Jan 2026	0001437782

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MIST	Common Shares	Sale	$1,125	-500	-0.14%	$2.25	346,721	07 Jan 2026	Direct	F1
transaction	MIST	Common Shares	Sale	$96,750	-43,000	-12%	$2.25	303,721	08 Jan 2026	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.
F2	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.265 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.265 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.